Tacrocap1 mg

Established / FDA-Approved Uses

• Prophylaxis of organ transplant rejection (systemic use): Tacrocap (oral or intravenous) is indicated, in combination with corticosteroids and other immunosuppressants (e.g., mycophenolate mofetil, azathioprine), for the prophylaxis of allograft rejection in patients receiving kidney, liver, or heart transplants. Extended-release formulations are used for kidney and, in some regions, liver transplant prophylaxis.
• Moderate-to-severe atopic dermatitis (topical use): Tacrocap ointment is indicated as a second-line, short-term and non-continuous chronic treatment of moderate-to-severe atopic dermatitis (eczema) in patients who have not responded adequately to, or who cannot tolerate, conventional therapies.

Guideline-Supported / Adjunct Uses (combination therapy required)

• Tacrocap is always used as part of a multi-drug immunosuppressive regimen (with corticosteroids and/or an antiproliferative agent) for transplant rejection prophylaxis; it is not used as monotherapy for this purpose.
• It is also used off-label, under specialist supervision, in the treatment of steroid-refractory acute or chronic graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation.

Off-Label Uses (specialist-directed, not FDA-approved)

• Selected autoimmune conditions such as lupus nephritis, nephrotic syndrome/minimal change disease, myasthenia gravis, and severe rheumatoid arthritis unresponsive to standard therapy, generally used only under rheumatology/nephrology specialist care.

Tacrocap must only be prescribed and monitored by physicians experienced in immunosuppressive therapy and management of transplant patients.

Each unit dosage form contains Tacrolimus Monohydrate as the active pharmaceutical ingredient, equivalent to the labeled strength of tacrolimus. Tacrolimus Monohydrate is available in multiple formulations, including immediate-release oral capsules, extended-release oral capsules/tablets, intravenous injection concentrate, and topical ointment (0.03% and 0.1%), each with formulation-specific inactive ingredients (excipients).

Tacrocap is the monohydrate salt form of tacrolimus, a macrolide-class calcineurin-inhibitor immunosuppressant originally derived from the soil fungus Streptomyces tsukubaensis. It is used systemically to prevent rejection of transplanted organs and, in a topical ointment formulation, to treat moderate-to-severe atopic dermatitis. Tacrocap works by suppressing T-lymphocyte activation, thereby reducing the immune response responsible for graft rejection and inflammatory skin disease.

Boxed Warning (systemic use): Increased risk of infections and malignancies (particularly lymphoma and skin cancers) due to immunosuppression. Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe Tacrocap.

Boxed Warning (topical use): Rare cases of malignancy (skin cancer, lymphoma) have been reported in patients using topical Tacrocap, although a causal relationship has not been established. Topical Tacrocap should be used only as second-line therapy, for short-term and intermittent (not continuous long-term) treatment, at the lowest effective dose.

Tacrocap belongs to the calcineurin-inhibitor class of immunosuppressant agents (macrolide immunosuppressants). It is pharmacologically distinct from, but mechanistically similar to, cyclosporine.

Mechanism of Action

Tacrolimus Monohydrate binds to an intracellular protein, FK-binding protein-12 (FKBP-12), forming a complex that inhibits calcineurin, a calcium/calmodulin-dependent phosphatase. Inhibition of calcineurin prevents dephosphorylation of the nuclear factor of activated T-cells (NFAT), blocking its translocation into the nucleus. This suppresses transcription of interleukin-2 (IL-2) and other cytokines, inhibiting T-lymphocyte activation and proliferation. This reduces both cellular and humoral immune responses responsible for transplant rejection and for the T-cell-mediated inflammation of atopic dermatitis.

Pharmacokinetics

Oral Tacrolimus Monohydrate is variably and incompletely absorbed (average bioavailability ~20-25%, food reduces absorption), is extensively bound to erythrocytes and plasma proteins, and is metabolized almost entirely by hepatic and intestinal CYP3A4/CYP3A5 enzymes, with elimination mainly via bile/feces. Whole-blood trough concentration monitoring is required to individualize systemic dosing because of a narrow therapeutic index and wide inter-patient pharmacokinetic variability. Topical Tacrolimus Monohydrate ointment has minimal, formulation- and severity-dependent systemic absorption, which decreases further as skin barrier function improves during treatment.

• Oral capsules/tablets: Take consistently either with or without food, at the same time each day, generally on an empty stomach for immediate-release capsules unless otherwise directed, to maintain stable blood levels; do not switch between Tacrocap brands or formulations without physician approval, as they are not interchangeable.
• Intravenous infusion: Administered only in a hospital/clinical setting by trained personnel as a continuous infusion; not for bolus injection.
• Topical ointment: For external skin use only; wash hands after application unless hands are the treated area; avoid contact with eyes and mucous membranes; do not use with occlusive dressings unless directed.

Clinically Significant Interactions (Systemic Use)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, erythromycin, ritonavir, diltiazem, grapefruit juice): significantly increase Tacrocap blood levels, raising nephrotoxicity/neurotoxicity risk; dose reduction and closer monitoring are required.
• Strong CYP3A4 inducers (e.g., rifampin, rifabutin, phenytoin, carbamazepine, St. John's Wort): significantly decrease Tacrocap blood levels, risking transplant rejection; concurrent use should generally be avoided or requires dose adjustment with close monitoring.
• Other nephrotoxic agents (e.g., aminoglycosides, amphotericin B, NSAIDs, cyclosporine): may increase the risk of additive nephrotoxicity when combined with Tacrocap.
• QT-interval-prolonging drugs: additive risk of QT prolongation and arrhythmia when combined with Tacrocap.
• Potassium-sparing diuretics, ACE inhibitors, ARBs, and potassium supplements: increased risk of hyperkalemia.
• Live attenuated vaccines: should be avoided during systemic Tacrocap therapy due to immunosuppression (see Precautions and Warnings).

Topical Use

Systemic interactions are unlikely with topical Tacrocap due to minimal absorption, but excessive alcohol intake may cause facial flushing/skin irritation shortly after application.

Systemic Use

• Common: tremor, headache, insomnia, diarrhea, nausea, hypertension, hyperglycemia, hyperkalemia, hypomagnesemia, renal impairment, paresthesia.
• Serious: nephrotoxicity, neurotoxicity (including tremor, confusion, seizures, and rare posterior reversible encephalopathy syndrome), new-onset diabetes after transplant, QT prolongation/arrhythmia, increased susceptibility to serious infections, and malignancies including lymphoma and skin cancer (see boxed warning under Description).

Topical Use

• Common: burning or stinging sensation at the application site (especially during the first few days), pruritus, skin erythema, and flu-like symptoms.
• Less common/serious: localized skin infections (e.g., folliculitis, herpes simplex flare), and rare reports of malignancy with long-term use (see boxed warning under Description).

Tacrocap crosses the placenta. Data in pregnant transplant recipients suggest it can be used when the potential benefit to the mother (maintaining graft function) justifies the potential risk to the fetus, but only under close specialist obstetric and transplant monitoring; transient neonatal hyperkalemia and renal dysfunction have been reported with systemic use in pregnancy. Tacrocap is excreted into human breast milk; breastfeeding is generally not recommended during systemic therapy due to potential effects on the infant. For topical use, application should be avoided on the nipple/areola area if breastfeeding, and use in pregnancy should be limited to situations where clearly needed, under physician guidance. Use only if clearly needed and only under direct medical supervision.

• Specialist monitoring required (systemic use): Regular monitoring of Tacrocap whole-blood trough concentrations, renal function, blood pressure, and blood glucose is essential, as nephrotoxicity, neurotoxicity, hypertension, hyperglycemia, and QT prolongation are recognized risks.
• Infection and malignancy risk: As with all immunosuppressants, Tacrocap increases susceptibility to infections (including opportunistic infections) and malignancies; see boxed warnings under Description.
• Live vaccines: Avoid administration of live attenuated vaccines during systemic immunosuppressive therapy with Tacrocap.
• Topical use precautions: Expect a burning/stinging sensation, especially at treatment initiation; minimize sun and UV light exposure (including sunlamps) and use sun protection during treatment; avoid use under occlusive dressings unless directed; not recommended for children below the labeled minimum age for the specific topical formulation; treatment should be short-term/intermittent rather than continuous.
• Do not use Tacrocap without regular physician follow-up; do not adjust the dose or switch products/brands without medical advice.

Overdose with Tacrocap may present with exaggerated pharmacologic effects, including nephrotoxicity, tremor, and other neurotoxic symptoms. There is no specific antidote. In case of a suspected overdose of Tacrocap, seek immediate medical attention or contact a poison control center right away; supportive care and, where clinically appropriate, general measures to reduce further absorption may be instituted by medical professionals. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Injectable formulations may require refrigeration prior to dilution as per the product label. Keep out of reach of children.

• Renal impairment: Tacrocap is itself nephrotoxic; dose adjustment based on trough levels and renal function monitoring is essential, and initial dosing at the lower end of the range is recommended in patients with pre-existing renal impairment.
• Hepatic impairment: Dose reduction is generally required in patients with significant hepatic impairment due to reduced drug clearance; close trough-level monitoring is essential.
• Elderly: No specific dose adjustment is established solely on the basis of age, but elderly patients should be monitored closely for renal function, blood pressure, and infection risk.
• Pediatric: See Pediatric Uses.

For transplant rejection prophylaxis, systemic Tacrocap is typically continued long-term (often lifelong) as directed by the transplant specialist, with dose adjustments over time based on trough levels and clinical status. For atopic dermatitis, topical Tacrocap should be used short-term to clear active lesions, then discontinued; continuous, uninterrupted long-term use is not recommended, and intermittent courses for flare management should only be used under physician guidance.

Tacrolimus Monohydrate is classified as a calcineurin-inhibitor immunosuppressant (macrolide immunosuppressant).

Tacrolimus Monohydrate inhibits calcineurin phosphatase activity by binding FKBP-12, blocking dephosphorylation and nuclear translocation of NFAT, thereby suppressing IL-2 gene transcription and T-lymphocyte activation and proliferation. This action underlies both its immunosuppressive effect in organ transplantation and its anti-inflammatory effect in atopic dermatitis.

C

Systemic Tacrocap is approved for use in pediatric organ transplant recipients, with weight-based dosing similar to or sometimes higher than adult mg/kg dosing, individualized to trough blood levels under pediatric transplant specialist supervision. Topical Tacrocap 0.03% ointment is approved for short-term and intermittent treatment of moderate-to-severe atopic dermatitis in children aged 2 to 15 years; it is not recommended for children under 2 years of age, in whom safety and efficacy have not been established. The 0.1% ointment strength is approved only for patients 16 years and older.